Latest GenomeDx Biosciences Stories
SAN DIEGO, May 18, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that the company has identified a genomic signature that is predictive of metastasis in patients with muscle invasive
SAN DIEGO, May 15, 2015 /PRNewswire/ -- GenomeDx Biosciences announced that three abstracts presented today at the American Urological Association Annual Meeting in New Orleans featuring the
SAN DIEGO, May 13, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that multiple studies featuring clinical data from the company's Decipher platform will be presented at the 2015
Presentations to Include Data from Bladder Cancer Application of Decipher SAN DIEGO, May 8, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that eight abstracts featuring
Data from Multiple Studies Include Potential Ability for Technology to Further Subtype Patients, Guide Treatment Decisions SAN DIEGO, Feb.
Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2015 ASCO Genitourinary Symposium SAN DIEGO, Feb.
Decipher is the first genomic test for postoperative prostate cancer to gain Medicare coverage SAN DIEGO, Jan.
First study to show that the genomic signature of prostate cancer can predict rapid development of metastatic disease in men who were managed conservatively after surgery SAN DIEGO, Dec.
Builds on initial collaboration with Mayo Clinic that led to the development and commercialization of Decipher in patients following prostate surgery SAN DIEGO, Nov.
SAN DIEGO, Oct.
- A handkerchief.
- In general, any miraculous portrait of Christ.